Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02334306 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
A Phase 2 study of Primary Sjögren's Syndrome, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 13
- Study locations
NCT02334306 is a Phase 2 study of Primary Sjögren's Syndrome that has completed, run by MedImmune. The registered enrollment target is 32 participants. The trial reports 13 study locations across 4 states.
The verdict
NCT02334306, a Phase 2 study of Primary Sjögren's Syndrome, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 13
- Study locations
Study Summary
A Phase 2a study to evaluate the efficacy and safety of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL AMG 557/MEDI5872
Study Locations (13)
Other
- Research Site - Brest
- Research Site - Le Kremlin-Bicêtre
- Research Site - Lille
- Research Site - Paris
- Research Site - Paris
- Research Site - Strasbourg
- Research Site - Stockholm
- Research Site - London
- Research Site - Newcastle upon Tyne
- Research Site - Swindon
California
- Research Site - San Francisco
Maryland
- Research Site - Bethesda
Pennsylvania
- Research Site - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-06-08 |
| Est. Completion | 2018-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02334306
The ClinicalTrials.gov registry entry for NCT02334306 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sjögren's Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02334306 reports 13 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT02334306 about?
NCT02334306 is a clinical study titled "A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome". A Phase 2a study to evaluate the efficacy and safety of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
What is the current status of trial NCT02334306?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2015-06-08. Estimated completion is 2018-08-13.
What conditions does trial NCT02334306 study?
This clinical trial studies the following conditions: Primary Sjögren's Syndrome.
What interventions are being tested in trial NCT02334306?
The interventions under investigation include: Placebo (OTHER), AMG 557/MEDI5872 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02334306?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02334306 being conducted?
This trial has 13 study locations across California, Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sjögren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
RECRUITING · Phase 2
-
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.